Kircher Malte, Herhaus Peter, Schottelius Margret, Buck Andreas K, Werner Rudolf A, Wester Hans-Jürgen, Keller Ulrich, Lapa Constantin
Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany.
Internal Medicine III, Hematology and Medical Oncology, Technische Universität München, Munich, Germany.
Ann Nucl Med. 2018 Oct;32(8):503-511. doi: 10.1007/s12149-018-1290-8. Epub 2018 Aug 13.
Given its prominent role in inflammation and cancer biology, the C-X-C motif chemokine receptor 4 (CXCR4) has gained a lot of attention in the recent years. This review gives a short overview of the physiology and pathology of chemokines and chemokine receptors and then focuses on the current experience of targeting CXCR4, using radiolabeled receptor ligands suitable for positron emission tomography (PET) imaging, in both hematologic and solid malignancy as well as in inflammatory conditions. Additionally, CXCR4-directed endoradiotherapy (ERT) as a new treatment option is discussed.
鉴于C-X-C基序趋化因子受体4(CXCR4)在炎症和癌症生物学中发挥的重要作用,近年来它受到了广泛关注。本文综述简要概述了趋化因子和趋化因子受体的生理学和病理学,然后重点介绍了在血液系统恶性肿瘤和实体恶性肿瘤以及炎症性疾病中,使用适用于正电子发射断层扫描(PET)成像的放射性标记受体配体靶向CXCR4的当前经验。此外,还讨论了CXCR4导向的内照射放射治疗(ERT)作为一种新的治疗选择。